Alector, Inc. (NASDAQ:ALEC) Receives Consensus Recommendation of “Hold” from Brokerages

Posted by Brian Himes on Sep 12th, 2026

Shares of Alector, Inc. (NASDAQ:ALEC – Get Free Report) have earned a consensus rating of “Hold” from the eight brokerages that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $3.6250.

Separately, Weiss Ratings raised shares of Alector from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th.

View Our Latest Stock Report on ALEC

Alector Price Performance

Shares of ALEC opened at $2.14 on Monday. Alector has a twelve month low of $1.09 and a twelve month high of $3.40. The stock’s 50 day moving average is $1.93 and its two-hundred day moving average is $2.07. The firm has a market capitalization of $238.95 million, a PE ratio of -1.95 and a beta of 0.65. The company has a current ratio of 5.26, a quick ratio of 5.26 and a debt-to-equity ratio of 0.80.

Alector (NASDAQ:ALEC – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.02. Alector had a negative return on equity of 531.03% and a negative net margin of 850.13%.The business had revenue of $3.32 million during the quarter, compared to the consensus estimate of $1.71 million. Research analysts anticipate that Alector will post -0.87 earnings per share for the current year.

Insider Buying and Selling

In other Alector news, CEO Arnon Rosenthal sold 72,606 shares of the business’s stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $2.66, for a total transaction of $193,131.96. Following the sale, the chief executive officer directly owned 2,294,600 shares in the company, valued at approximately $6,103,636. The trade was a 3.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Neil Berkley sold 29,251 shares of the firm’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $2.66, for a total value of $77,807.66. Following the completion of the transaction, the chief financial officer owned 350,649 shares of the company’s stock, valued at approximately $932,726.34. This represents a 7.70% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 111,303 shares of company stock worth $295,633. Insiders own 8.30% of the company’s stock.

Hedge Funds Weigh In On Alector

Several hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new position in shares of Alector during the 2nd quarter worth approximately $15,774,000. Vanguard Group Inc. increased its position in Alector by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 6,034,659 shares of the company’s stock worth $17,863,000 after purchasing an additional 46,955 shares in the last quarter. Nantahala Capital Management LLC purchased a new stake in Alector during the 2nd quarter worth about $8,679,399. Foresite Capital Management IV LLC acquired a new position in Alector in the 4th quarter valued at about $6,064,000. Finally, Merck & Co. Inc. purchased a new position in Alector in the 2nd quarter valued at about $7,126,896. 85.83% of the stock is currently owned by hedge funds and other institutional investors.

Alector Company Profile

(Get Free Report)

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.